公开(公告)号：US20240252441A1

公开(公告)日：2024-08-01

申请号：US18425556

申请日：2024-01-29

Applicant: CRITITECH, INC.

Inventor： Gere S. DIZEREGA ,  Michael BALTEZOR ,  Sam CAMPBELL ,  Charles J. DECEDUE ,  Matthew MCCLOREY ,  Holly MAULHARDT

IPC: A61K9/16 ,  A61K9/00 ,  A61K31/337 ,  A61K39/00 ,  C07K16/28

CPC classification number: A61K9/1652 ,  A61K31/337 ,  C07K16/2818 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/0053 ,  A61K2039/54

Abstract: Disclosed are combination therapy methods useful for the therapeutic treatment of cancer by combining local administration of compositions containing antineoplastic particles, such as taxane particles, with systemic administration of compositions containing immunotherapeutic agents. Local administration methods include topical application, pulmonary administration, intratumoral injection, intraperitoneal injection, and intracystic injection.

公开(公告)号：US20210387961A1

公开(公告)日：2021-12-16

申请号：US17401654

申请日：2021-08-13

Applicant: CRITITECH, INC.

Inventor： Mark WILLIAMS ,  Jacob SITTENAUER ,  Shelby CLARK ,  Joseph FARTHING ,  Michael BALTEZOR ,  Matthew MCCLOREY

IPC: C07D401/10 ,  A61P31/04 ,  A61K9/14 ,  A61K9/00

Abstract: The present disclosure relates to ciprofloxacin polymorphs and their use in treating infections.

公开(公告)号：US20200163928A1

公开(公告)日：2020-05-28

申请号：US16776919

申请日：2020-01-30

Applicant: CRITITECH, INC.

Inventor： Michael BALTEZOR ,  Joseph FARTHING ,  Jake SITTENAUER ,  Jahna ESPINOSA ,  Samuel CAMPBELL ,  Matthew MCCLOREY ,  Julia K. FISCHER ,  Mark D. WILLIAMS ,  Gary E. CLAPP

IPC: A61K31/337 ,  A61K9/51 ,  A61K9/16 ,  B05B13/02 ,  A61K9/10 ,  A61K9/00 ,  A61J3/02 ,  B01J3/00 ,  B05B1/34 ,  B01D46/24 ,  B01J4/00 ,  B01J19/10 ,  B01J2/04 ,  A61K9/14 ,  B01J19/26 ,  B01J3/02

Abstract: Compositions are provided that include having at least 95% by weight of a taxane, or a pharmaceutically acceptable salt thereof, where the particles have a mean bulk density between about 0.050 g/cm3 and about 0.15 g/cm3, and/or a specific surface area (SSA) of at least 18 m2/g, 20 m2/g, 25 m2/g, 30 m2/g, 32 m2/g, 34 m2/g, or 35 m2/g. Methods for making and using such compositions are also provided.

公开(公告)号：US20170224650A1

公开(公告)日：2017-08-10

申请号：US15499397

申请日：2017-04-27

Applicant: CRITITECH, INC.

Inventor： Michael BALTEZOR ,  Joseph FARTHING ,  Jake SITTENAUER ,  Jahna ESPINOSA ,  Samuel CAMPBELL ,  Matthew MCCLOREY ,  Julia K. FISCHER ,  Mark D. WILLIAMS

IPC: A61K31/337 ,  B01J3/00 ,  B01J3/02 ,  A61K9/16

CPC classification number: A61K31/337 ,  A61J3/02 ,  A61K9/0019 ,  A61K9/10 ,  A61K9/14 ,  A61K9/1605 ,  A61K9/1682 ,  A61K9/1688 ,  A61K9/5192 ,  B01D46/24 ,  B01D2271/02 ,  B01J2/04 ,  B01J3/008 ,  B01J3/02 ,  B01J4/002 ,  B01J19/10 ,  B01J19/26 ,  B05B1/3489 ,  B05B13/0278 ,  B05D2401/90

Abstract: Compositions are provided that include having at least 95% by weight of a taxane, or a pharmaceutically acceptable salt thereof, where the particles have a mean bulk density between about 0.050 g/cm3 and about 0.15 g/cm3, and/or a specific surface area (SSA) of at least 18 m2/g, 20 m2/g, 25 m2/g, 30 m2/g, 32 m2/g, 34 m2/g, or 35 m2/g. Methods for making and using such compositions are also provided.

公开(公告)号：US20200247780A1

公开(公告)日：2020-08-06

申请号：US16650670

申请日：2018-09-28

Applicant: CRITITECH, INC.

Inventor： Mark WILLIAMS ,  Jacob SITTENAUER ,  Shelby CLARK ,  Joseph FARTHING ,  Michael BALTEZOR ,  Matthew MCCLOREY

IPC: C07D401/10 ,  A61K9/14 ,  A61K9/00 ,  A61P31/04

Abstract: The present disclosure relates to ciprofloxacin polymorphs and their use in treating infections.

公开(公告)号：US20200246355A1

公开(公告)日：2020-08-06

申请号：US16650961

申请日：2018-09-28

Applicant: CRITITECH, INC.

Inventor： Michael BALTEZOR ,  Matthew MCCLOREY ,  Joseph S. FARTHING ,  Mark WILLIAMS ,  Jacob SITTENAUER

IPC: A61K31/569 ,  A61K9/00 ,  A61K9/16 ,  A61K31/496 ,  A61P9/00

Abstract: Disclosed herein are particles of at least 95% by weight of a glucocorticoid that have a specific surface area of at least 10 m2/g, methods for making, such particles, and methods for their use as therapeutics. Also disclosed herein are particles of at least 95% by weight of an indolinone that have a specific surface area of at least 10 m2/g, methods for making such particles, and methods for-their use as therapeutics.

公开(公告)号：US20190209514A1

公开(公告)日：2019-07-11

申请号：US16239527

申请日：2019-01-04

Applicant: CRITITECH, INC.

Inventor： Gere S. DIZEREGA ,  Michael BALTEZOR ,  Charles J. DECEDUE ,  Sam CAMPBELL ,  Matthew MCCLOREY

IPC: A61K31/337 ,  A61K9/00 ,  A61K9/08 ,  A61K9/10 ,  A61K9/14 ,  A61P35/00

CPC classification number: A61K31/337 ,  A61K9/0019 ,  A61K9/0034 ,  A61K9/08 ,  A61K9/10 ,  A61K9/14 ,  A61K9/16 ,  A61K47/26 ,  A61P35/00

Abstract: Disclosed herein are methods for treating and inhibiting the recurrence of bladder cancer by local administration of compositions comprising taxane particles such as docetaxel particles. Administration methods include intratumoral injection, direct injection into surgical tumor resection sites, and intravesical instillation.

公开(公告)号：US20160374953A1

公开(公告)日：2016-12-29

申请号：US15261108

申请日：2016-09-09

Applicant: CRITITECH, INC.

Inventor： Michael BALTEZOR ,  Joseph FARTHING ,  Jake SITTENAUER ,  Jahna ESPINOSA ,  Samuel CAMPBELL ,  Matthew MCCLOREY ,  Julia K. FISCHER ,  Mark D. WILLIAMS

IPC: A61K9/51 ,  A61K31/337

CPC classification number: A61K31/337 ,  A61J3/02 ,  A61K9/0019 ,  A61K9/10 ,  A61K9/14 ,  A61K9/1605 ,  A61K9/1682 ,  A61K9/1688 ,  A61K9/5192 ,  B01D46/24 ,  B01D2271/02 ,  B01J2/04 ,  B01J3/008 ,  B01J3/02 ,  B01J4/002 ,  B01J19/10 ,  B01J19/26 ,  B05B1/3489 ,  B05B13/0278 ,  B05D2401/90

Abstract: Compositions are provided that include having at least 95% by weight of a taxane, or a pharmaceutically acceptable salt thereof, where the particles have a mean bulk density between about 0.050 g/cm3 and about 0.15 g/cm3, and/or a specific surface area (SSA) of at least 18 m2/g, 20 m2/g, 25 m2/g, 30 m2/g, 32 m2/g, 34 m2/g, or 35 m2/g. Methods for making and using such compositions are also provided.

Abstract translation: 提供的组合物包括具有至少95重量％的紫杉烷或其药学上可接受的盐，其中颗粒的平均堆积密度为约0.050g / cm 3至约0.15g / cm 3，和/或比表面积 面积（SSA）至少为18m2 / g，20m2 / g，25m2 / g，30m2 / g，32m2 / g，34m2 / g或35m2 / g。 还提供了制备和使用这些组合物的方法。

公开(公告)号：US20240226116A1

公开(公告)日：2024-07-11

申请号：US18608226

申请日：2024-03-18

Applicant: CRITITECH, INC.

Inventor： Michael BALTEZOR ,  Matthew MCCLOREY ,  Joseph S. FARTHING ,  Mark WILLIAMS ,  Jacob SITTENAUER

IPC: A61K31/569 ,  A61K9/00 ,  A61K9/16 ,  A61K31/496 ,  A61P9/00

CPC classification number: A61K31/569 ,  A61K9/0075 ,  A61K9/1688 ,  A61K31/496 ,  A61P9/00

Abstract: Disclosed herein are particles of at least 95% by weight of a glucocorticoid that have a specific surface area of at least 10 m2/g, methods for making, such particles, and methods for their use as therapeutics. Also disclosed herein are particles of at least 95% by weight of an indolinone that have a specific surface area of at least 10 m2/g, methods for making such particles, and methods for-their use as therapeutics.

公开(公告)号：US20210214683A1

公开(公告)日：2021-07-15

申请号：US17057945

申请日：2019-04-12

Applicant: CRITITECH, INC.

Inventor： Gere S. DIZEREGA ,  Holly MAULHARDT ,  Michael BALTEZOR ,  Sam CAMPBELL ,  Charles J. DECEDUE ,  William JOHNSTON ,  Matthew MCCLOREY ,  James VERCO

IPC: C12N5/0783 ,  A61K39/00 ,  A61P35/00 ,  A61K31/337

Abstract: Disclosed are methods for the isolation of tumor-specific immune cells from subjects that have a malignant tumor and have received local administration of a composition comprising taxane particles to the malignant tumor, and use of such isolated immune cells in compositions for adoptive cell therapy and cancer vaccines.